This case highlights the challenges in using PD-1 inhibitors to manage metastatic cancer in VEXAS syndrome, indicating important clinical considerations.
Metastatic Cutaneous Squamous Cell Carcinoma in VEXAS Syndrome. This case highlights the clinical dilemma of using PD-1 inhibitors in patients with VEXAS syndrome, emphasizing the delicate balance between therapeutic efficacy and immune-related toxicity. The use of the PD-1 inhibitor in patients with VEXAS syndrome presents a significant clinical challenge, requiring a careful risk-benefit assessment.
No takes yet. Share an insight, caveat, or question.
Bongiovanni et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: